Integrative Biomedical Research

Ai, M.-Y., & Chang, W.-L. (2026). Comparative effectiveness and safety of monotherapy and defined combination regimens for Stenotrophomonas maltophilia infections: A network meta-analysis. Germs, 16(1), 1–18.

Alexandre, K., Leysour de Rohello, F., Dahyot, S., Etienne, M., Tiret, I., Gillibert, A., Pestel-Caron, M., & Caron, F. (2021). Efficacy of temocillin against MDR Enterobacterales: A retrospective cohort study. Journal of Antimicrobial Chemotherapy, 76(3), 784–788. https://doi.org/10.1093/jac/dkaa502

Animasaun, O. S., Abdullahi, I. N., Akomolafe, B. K., Balogun, M. S., Gobir, I. B., Niyang, P. M., Animasaun, O. P., Ogundana, N. F., Raji, Y. E., Njoku, K. A., Ikelionwu, J. O., Sanni, F. O., Akinjoko, F. E., Ogundokun, O. O., Kehinde, A. O., & Ogbolu, D. O. (2026). Epidemiology and antimicrobial resistance patterns of Gram-negative pathogens recovered from clinical specimens in Nigeria. IJID Regions, 20, 100952. https://doi.org/10.1016/j.ijregi.2026.100952

Ataei-Alamdari, S., Alimardani, F., Afkhami, H., Kashfi, M., & Yousefi, M. H. (2026). Synergistic potential of probiotics and bacteriophages in combating multidrug-resistant microbial infections: A novel therapeutic strategy for the post-antibiotic era. New Microbes and New Infections, 72, 101804.

Augello, M., Di Bartolomeo, F., Varisco, B., Timelli, L., Bartoletti, M., Bonfanti, P., & Caston, J. J. (2025). Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: The multicentre retrospective CEFI-BAC study. International Journal of Infectious Diseases, 163, 108305. https://doi.org/10.1016/j.ijid.2025.108305

Balakrishnan, I., Awad-El-Kariem, F. M., Aali, A., Kumari, P., & Heard, K. L. (2011). Temocillin for the treatment of multi-drug resistant Enterobacteriaceae infections. Journal of Antimicrobial Chemotherapy, 66(11), 2622–2625. https://doi.org/10.1093/jac/dkr315

Bayart, J., Drouet, J., Peycelon, M., Mariani, P., Le Roux, E., Husain, M., Agar, J., Bonacorsi, S., & Caseris, M. (2024). Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: A monocentric exposed/non-exposed study. Journal of Antimicrobial Chemotherapy, 79(4), 918–922. https://doi.org/10.1093/jac/dkae021

Bleibtreu, A., Dortet, L., Bonnin, R. A., Wyplosz, B., Sacleux, S. C., & Mihaila, L. (2021). Susceptibility testing is key for the success of cefiderocol treatment: A retrospective cohort study. Microorganisms, 9(2), 282. https://doi.org/10.3390/microorganisms9020282

Brousse, X., Lahouati, M., Dias Meireles, V., Rignol, L., Bientz, L., Xuereb, F., & Dauchy, F.-A. (2025). Real-world use of temocillin in the treatment of complicated urinary tract infections and bone and joint infections caused by AmpC β-lactamase-producing Enterobacterales. JAC-Antimicrobial Resistance, 7(1), dlae199. https://doi.org/10.1093/jacamr/dlae199

Carbonell, N., Oltra, M. R., & Clari, M. Á. (2024). Stenotrophomonas maltophilia: The landscape in critically ill patients and optimising management approaches. Antibiotics, 13(7), 577.

Cosimi, L., Zerbato, V., Grasselli Kmet, N., Oliva, A., Cogliati Dezza, F., Geremia, N., Cattaneo, D., Nadrah, K., Pirs, M., Saletinger, R., Nunnari, A., Mearelli, F., Di Girolamo, F. G., Avena, G., Russo, R., Fabiani, C., Venturini, S., Principe, L., & Nicolò, G. M. (2025). Temocillin: A narrative review of its clinical reappraisal. Antibiotics, 14(9), 859. https://doi.org/10.3390/antibiotics14090859

Delory, T., Gravier, S., Le Pluart, D., Gaube, G., Simeon, S., Davido, B., Piet, E., Lepeule, R., Lesprit, P., & Lafaurie, M. (2021). Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: A multicenter matched case-control study. International Journal of Antimicrobial Agents, 58(3), 106361. https://doi.org/10.1016/j.ijantimicag.2021.106361

Deng, S.-M., Wei, W.-J., Duan, T.-J., & Jiang, Z.-P. (2026). Risk factors and outcomes of bloodstream infection with multidrug-resistant bacteria in adult patients with acute leukemia. Journal of Infection and Public Health, 19, 103088. https://doi.org/10.1016/j.jiph.2025.103088

Di Bartolomeo, F., Augello, M., & Marchetti, G. (2026). Cefiderocol in clinical practice: From randomised trials to real-world evidence in the management of multidrug-resistant Gram-negative bacterial infections. Journal of Infection, 93, 106821. https://doi.org/10.1016/j.jinf.2026.106821

Dinh, A. S., Le Banner, E., Camelena, F., Larcher, R., Pantel, A., Melica, G., & Soueges, S. (2022). Real-world multicentre study of temocillin treatment of infections caused by ESBL-producing Enterobacterales: TEMO-ESBL. Journal of Infection, 84(4), 393–395. https://doi.org/10.1016/j.jinf.2022.01.018

Duhaniuc, A., Paduraru, D., Nastase, E.-V., Trofin, F., Iancu, L.-S., Sima, C.-M., & Dorneanu, O.-S. (2024). Multidrug-resistant bacteria in immunocompromised patients. Pharmaceuticals, 17(9), 1151.

Edlund, C., Ternhag, A., Skoog Ståhlgren, G., Edquist, P., Östholm Balkhed, Å., Athlin, S., Månsson, E., Tempé, M., Bergström, J., & Giske, C. G. (2022). The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: A randomised multicentre clinical trial in Sweden. The Lancet Infectious Diseases, 22(3), 390–400. https://doi.org/10.1016/S1473-3099(21)00407-2

Enoch, D. A., Al-Hasan, M. N., Lahr, B. D., Eckel-Passow, J. E., & Baddour, L. M. (2022). Clinical outcomes of temocillin use for complicated urinary tract infections caused by ESBL-producing Enterobacterales in outpatients. JAC-Antimicrobial Resistance, 4(2), dlac086. https://doi.org/10.1093/jacamr/dlac086

Falcone, M., Tiseo, G., Leonildi, A., Della Sala, L., Vecchione, A., Barnini, S., & Menichetti, F. (2022). Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 66(5), e02142-21. https://doi.org/10.1128/aac.02142-21

Habayeb, H., Sajin, B., Patel, K., Grundy, C., Al-Dujaili, A., & Van de Velde, S. (2015). Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: Results from a retrospective audit. European Journal of Clinical Microbiology & Infectious Diseases, 34(8), 1693–1699. https://doi.org/10.1007/s10096-015-2400-y

Heard, K. L., Killington, K., Mughal, N., Moore, L. S. P., & Hughes, S. (2021). Clinical outcomes of temocillin use for invasive Enterobacterales infections: A single-centre retrospective analysis. JAC-Antimicrobial Resistance, 3(1), dlab005. https://doi.org/10.1093/jacamr/dlab005

Hou, Y., Zhang, L., Li, H., Zhong, L., Zhang, H., Tang, T., Zheng, X., Zhou, R., Lv, S., Que, G., Tan, B., Chen, L., Hsu, Y., Hu, H., Shen, J., Yue, B., Chen, K., Di, W., Guo, L., Chen, L., Yu, H., Huang, K., Huang, X., Pan, C., Yang, H., & Pan, L. (2026). Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: A multicenter prospective cohort study. International Journal of Antimicrobial Agents, 67, 107795. https://doi.org/10.1016/j.ijantimicag.2026.107795

Jaber, F., El Rawas, S., Faraj, S., Al Zoghby, L., Bou Khalil, J., Abdulhalim, R., Al Accad, Y., & Kanafani, Z. A. (2026). Value of the Pitt bacteremia score in predicting the outcome of nonbacteremic patients with infections caused by multidrug-resistant organisms. International Journal of Infectious Diseases, 171, 108960.

Juzbašic, T., Andrijaševic, N., Ferencak, I., Juric, D., Šoprek, S., Poje Janeš, V., Žmak, L., Tambic Andraševic, A., & Gveric Grginic, A. (2025). Emergence of multidrug-resistant Campylobacter jejuni in a common variable immunodeficiency patient: Evolution of resistance under the selective antibiotic pressure. Tropical Medicine and Infectious Disease, 10(6), 165.

Kandil, H., Larcher, R., Pantel, A., Melica, G., & Soueges, S. (2023). Fast de-escalation of carbapenems using temocillin in critically ill patients: A retrospective monocentric analysis. Annals of Intensive Care, 13(1), 52. https://doi.org/10.1186/s13613-023-01121-w

Karruli, A., Massa, A., Andini, R., Marrazzo, T., Ruocco, G., Zampino, R., & Durante-Mangoni, E. (2023). Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: A real-life, single-centre experience. International Journal of Antimicrobial Agents, 61(2), 106723. https://doi.org/10.1016/j.ijantimicag.2022.106723

Kent, L., Jousset, A. B., Dortet, L., & Bonnin, R. A. (2008). Retrospective multicenter review of temocillin use for acute pulmonary exacerbations in patients with cystic fibrosis. Journal of Cystic Fibrosis, 7(1), 43–48. https://doi.org/10.1016/j.jcf.2007.04.004

Lahouati, M., Brousse, X., Dias Meireles, V., Rignol, L., Bientz, L., Xuereb, F., & Dauchy, F.-A. (2024). Real-life use of temocillin in the treatment of bone and joint infections due to extended spectrum β-lactamase-producing Enterobacterales. JAC-Antimicrobial Resistance, 6(4), dlae171. https://doi.org/10.1093/jacamr/dlae171

Laterre, P. F., De Jongh, R., Hens, R., Basma, V., Mouton, J. W., Tulkens, P. M., & Carryn, S. (2015). Continuous versus intermittent infusion of temocillin, a directed-spectrum penicillin for intensive care patients with nosocomial pneumonia: Stability, compatibility, population pharmacokinetic studies, and breakpoint selection. Journal of Antimicrobial Chemotherapy, 61(2), 382–388. https://doi.org/10.1093/jac/dkm431

Mafe, A. N., & Büsselberg, D. (2025). Phage therapy in managing multidrug-resistant (MDR) infections in cancer therapy: Innovations, complications, and future directions. Pharmaceutics, 17(7), 820.

Mamona Kilu, C., Menvielle, C., Cataldi, A., Hamon, A., Duran, C., Mwamba, C., Tesmoingt, C., Bouabdallah-Perrin, L., Touche, P., & Chanh Hew Wai, A. (2024). Effectiveness of temocillin in treatment of non-urinary tract infections caused by ESBL-producing Enterobacterales and risk factors for failure. JAC-Antimicrobial Resistance, 6(6), dlae164. https://doi.org/10.1093/jacamr/dlae164

Muggeo, P., Galaverna, F., Chiusaroli, L., Perruccio, K., Coccia, P., Baccelli, F., Boccieri, E., Rosignoli, C., De Leonardis, F., Santoro, N., & Cesaro, S. (2026). Cefiderocol in children with hematologic malignancies—The multicenter retrospective experience of the Infection Working Group of the Italian Pediatric Hematology and Oncology Association (AIEOP). Journal of Clinical Medicine, 15(8), 3100. https://doi.org/10.3390/jcm15083100

Oliva, A., Liguori, L., Covino, S., Petrucci, F., Cogliati-Dezza, F., Curtolo, A., & Venditti, M. (2024). Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: A single-center, observational study. European Journal of Clinical Microbiology & Infectious Diseases, 43(6), 1149–1160. https://doi.org/10.1007/s10096-024-04812-7

Oosterbos, J., Schalkwijk, M., Thiessen, S., Oris, E., Coppens, G., Lagrou, K., & Steensels, D. (2022). Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: A Belgian single-centre retrospective study. JAC-Antimicrobial Resistance, 4(2), dlac086. https://doi.org/10.1093/jacamr/dlac086

Palermo, G., Medaglia, A. A., Pipitò, L., Rubino, R., Costantini, M., Accomando, S., & Cascio, A. (2023). Cefiderocol efficacy in a real-life setting: Single-centre retrospective study. Antibiotics, 12(4), 746. https://doi.org/10.3390/antibiotics12040746

Piccica, M., Spinicci, M., Botta, A., Bianco, V., Lagi, F., Graziani, L., & Bartoloni, A. (2023). Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: An Italian multicentre real-life experience. Journal of Antimicrobial Chemotherapy, 78(11), 2752–2761. https://doi.org/10.1093/jac/dkad301

Rauch, S. G., Potter, M. H., & Kobic, E. (2025). A retrospective study of cefiderocol utilization and associated outcomes at an academic medical center. Infectious Disease Reports, 17(1), 12–19. https://doi.org/10.3390/idr17010002

Ravi, K., & Singh, B. (2024). ESKAPE: Navigating the global battlefield for antimicrobial resistance and defense in hospitals. Bacteria, 3(2), 76–98.

Sakagianni, A., Koufopoulou, C., Koufopoulos, P., Feretzakis, G., Anastasiou, A., Theodorakis, N., & Myrianthefs, P. (2025). Influence of microbiome interactions on antibiotic resistance development in the ICU environment: Insights and opportunities with machine learning. Acta Microbiologia Hellenica, 70, 14.

Sekowska, A., Czyzewski, K., Jaremek, K., Zalas-Wiecek, P., Zajac-Spychala, O., Wachowiak, J., Szmydki-Baran, A., Hutnik, L., Gietka, A., Gryniewicz-Kwiatkowska, O., Semczuk, K., Dzierzanowska-Fangrat, K., Czogala, W., Balwierz, W., Zak, I., Tomaszewska, R., Szczepanski, T., Bien, E., Irga-Jaworska, N., Machnik, K., Urbanska-Rakus, J., Pajak, S., Plonowski, M., Krawczuk-Rybak, M., Królak, A., Ociepa, T., Urasinski, T., Wawryków, P., Peregud-Pogorzelski, J., Brzeski, T., Mycko, K., Manko-Glinska, H., Badowska, W., Urbanek-Dadela, A., Karolczyk, G., Stolpa, W., Skowron-Kandzia, K., Mizia-Malarz, A., Pierlejewski, F., Mlynarski, W., Musial, J., Chaber, R., Zawitkowska, J., Zaucha-Prazmo, A., Drabko, K., Gozdzik, J., Fraczkiewicz, J., Salamonowicz-Bodzioch, M., Kalwak, K., & Styczynski, J. (2024). Infections with Klebsiella pneumoniae in children undergoing anticancer therapy or hematopoietic cell transplantation: A multicenter nationwide study. Journal of Clinical Medicine, 13(14), 4078. https://doi.org/10.3390/jcm13144078

Singer, C. E., Popescu, A. I. S., Varu?, R. M., Popescu, M., Loredana, D., Radivojevic, K., & Octavia, P. I. (2024). Bacterial pathogen profiles and antibiotic resistance in pediatric leukemia patients: Insights for optimizing infection management in immunocompromised children. Antibiotics, 13(12), 1234. https://doi.org/10.3390/antibiotics13121234

Soueges, S., Faure, E., Parize, P., Lanternier-Dessap, F., Lecuyer, H., Huynh, A., Martin-Blondel, G., Gaborit, B., Blot, M., Magallon, A., Blanchard, E., Brousse, X., Lahouati, M., Brunel, A.-S., Le Banner, E., Camelena, F., Larcher, R., Pantel, A., Melica, G., Razazi, K., Danion, F., Schramm, F., Dumitrescu, O., Hoellinger, B., & Ader, F. (2025). Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID. Journal of Infection, 90(1), 106376. https://doi.org/10.1016/j.jinf.2024.106376

Torre-Cisneros, J., et al. (2025). PERSEUS: Real-world early-access experience with cefiderocol in Spain [Multicentre retrospective study]. As cited in Cosimi et al. (2025) and related secondary sources.

Van den Broucke, E., Thijs, L., Desmet, S., Vander Elst, L., Gijsen, M., Mylemans, M., Van de Gaer, O., Peetermans, W. E., Quintens, C., & Spriet, I. (2022). Clinical efficacy of temocillin standard dosing in patients treated with outpatient antimicrobial therapy. Pharmaceutics, 14(11), 2289. https://doi.org/10.3390/pharmaceutics14112289

Vougiouklakis, G., Tsioutis, C., Vasileiadi, N., Alexakis, K., Spernovasilis, N., & Agouridis, A. P. (2025). Ceftazidime/avibactam monotherapy versus other antibiotics: Where do we stand? Pathogens, 14(11), 1119.

Zingg, S., Nicoletti, G. J., Kuster, S., Junker, M., Widmer, A., & Egli, A. (2020). Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: Real-world experience from a case series and review of the literature. Open Forum Infectious Diseases, 7(6), ofaa185. https://doi.org/10.1093/ofid/ofaa185